Diagnostics During and Beyond the Pandemic

Sara Brenner, MD, MPH
Center for Devices & Radiological Health
Food and Drug Administration
June 12, 2020
Protecting & Promoting Public Health

*During a Pandemic*

- In Vitro Diagnostics in the era of COVID-19
  - Emergency Use
  - Viral nucleic acid, direct antigen, antibody
- Balance of risks and benefits
  - Safety & innovation
- Testing as part of a larger strategy
  - Hierarchy of controls & risk mitigation
  - Infection control practices
How will diagnostics be used and how might they change over the course of the pandemic?
Semantic Harmonization and Interoperability Enhancement for Laboratory Data (SHIELD): Enables mission critical downstream activities

- Improve the speed and accuracy of reporting
- Improve diagnostic data quality
- Identify shortages
- Improve downstream integration into and across healthcare system platforms (e.g. EHRs)
- Support clinical trials by linking diagnostics, interventional, and therapeutic data over time
- Assess test quality and performance, including clinical validity, by linking lab/Dx data with clinical and outcomes data by leveraging and harmonizing RWD and RWE prospectively
• SARS-CoV-2 Dx Data Harmonization – Mapping Tool at CDC’s Division of Laboratory Systems website:
  LOINC LIVD Test Code Mapping for SARS-CoV-2 Tests

• Test developers or manufacturers may contact FDA at SHIELD-LabCodes@fda.hhs.gov for information about verifying codes with CDC and its partners in this project, and to provide feedback
Regan Udall Foundation Diagnostics Evidence Accelerator: Using RWD to Evaluate COVID-19 Diagnostic Testing

• While traditional test methods are underway, studies using RWD may provide important complementary information about real world patterns of use, test performance, and immunity
• Contemporary retrospective and prospective RWD sources are of progressively higher quality, and new methods have improved reliability of results
• A coordinated program of diagnostic testing research using RWD could rapidly generate useful evidence to inform clinical, public health, and policy decisions
• TEST: To generate evidence on real world test performance of SARS-CoV-2 molecular diagnostics, direct antigen, and antibody tests

• PATIENT: To improve understanding of the pathophysiology of disease including the development of antibodies, immune response, and immunity in patients with SARS-CoV-2 infection (by diagnostic testing and/or clinical assessment)

• POPULATION: To estimate the prevalence of SARS-CoV-2 infection, recovery (presence and persistence of antibodies over time) and reinfection for different populations, analyzed by geography, public health interventions, and other characteristics

• SYSTEM: To promote the uptake of COVID SHIELD data standards within clinical labs to improve the ability to address diagnostic testing questions
Rapid Acceleration of Diagnostics (RADx): Key Component of Operation Warp Speed

- Fast-track technology development program that leverages NIH Point-of-Care Technology Research Network (POCTRN)
- Innovative solutions that build the U.S. capacity for SARS-CoV-2 testing up to 100-fold above what is achievable with standard approaches as soon as late summer 2020
- Early & advanced stage transformative technologies to improve analytical performance, enhance operational performance, and improve access and reduce cost of testing
- Driving toward at-home or at-anywhere diagnostics coupled with digital health tools
Data & Public Health Decision-Making: Evidence-based decision making relies on comprehensive, high quality data

- Core data elements across different categories must be harmonized and integrated (e.g. diagnostic, specimen, clinical, demographic data)
- Increasing granularity of data at different levels enables evidence-based decision-making
  - Federal / National: real-time, high-level tracking, policy-making, resource utilization, security
  - State / Local: Contact tracing, containment of outbreaks, mitigation
  - Patient/ Physician: prevention, diagnosis, treatment, recovery

HHS Announces New Laboratory Data Reporting Guidance for COVID-19 Testing (June 4, 2020)

- COVID-19 Pandemic Response, Laboratory Data Reporting: CARES Act Section 18115
MDIC Framework on RWE for IVDs

Real-World Clinical Evidence Generation: Advancing Regulatory Science and Patient Access for In Vitro Diagnostics (IVDs)

• Focuses on the use and potential value of RWE to support regulatory decision-making for medical devices

• Support FDA and industry when considering when and how RWD, appropriate designs, and statistical methods including modeling to generate RWE might be incorporated into product development and regulatory decision-making

• Highlights issues pertinent to clinical validation of RWD in pre-market and post-market regulatory decision-making of IVD devices
Questions about COVID-19 IVD EUAs: CDRH-EUA-Templates@fda.hhs.gov

EUA webpage: https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations


Questions about laboratory data harmonization for COVID-19 testing: SHIELD-LabCodes@fda.hhs.gov
